The FDA awarded priority review vouchers to two companies for psilocybin in depression and one for methylone in PTSD, without naming the firms.
A separate FDA move authorized initial testing of an ibogaine-related drug for alcohol use disorder, developed by DemeRx, led by neurologist Deborah Mash.
The Trump administration's push follows growing support among veterans and political allies, with concerns raised over political favoritism in voucher allocation and the safety of psychedelic treatments.
Beyond approving new drugs, what is the plan to build a national psychedelic therapy infrastructure?
As the U.S. fast-tracks psychedelics, are we overlooking decades of serious safety warnings?
With psychedelic therapy approvals looming, who will be qualified to administer these powerful treatments?
Will breakthrough psychedelic treatments become a luxury for the wealthy or accessible to everyone?
Ibogaine shows promise for addiction but carries fatal risks. How will patient safety be guaranteed?
How exactly do these substances 'rewire' the brain to combat chronic mental illness?